A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy

Wei Mu, Xiaolu Long, Haodong Cai, Caixia Chen, Guang Hu, Yaoyao Lou, Shugang Xing, Di Wang, Jue Wang, Min Xiao, Kun Wang, Zhongyi Sun, Chunrui Li, Jianfeng Zhou, Liting ChenFrontiers in Pharmacology 2022 · DOI

TL;DR

This paper develops a population pharmacokinetic (PopPK) model for a novel fully human BCMA-targeting CAR T-cell therapy (CT103A) in multiple myeloma patients. The model reveals that long-term persistence of CT103A is primarily driven by a robust memory CAR T-cell fraction, rather than clonal evolution, and identifies extramedullary spreading as a factor that reduces peak CAR T-cell concentration.

What Problem Does This Paper Address?

CAR T-cell therapies are revolutionary "living drugs" derived from a patient's own cells, offering new hope for difficult-to-treat cancers like multiple myeloma. However, understanding their behavior within the body – their pharmacokinetics (PK) – is complex and crucial for optimizing efficacy, safety, and dosing. Unlike traditional drugs, CAR T-cells expand, persist, and can even evolve. Previous PK studies have focused on other CAR T-cell products, often in different patient populations (e.g., pediatric leukemia). This study addresses the need for a PK model specifically for CT103A, a fully human BCMA-targeting CAR T-cell therapy, in adult patients with relapsed/refractory multiple myeloma, aiming to explain its observed long-term persistence.

Methods

The researchers employed a population pharmacokinetic (PopPK) modeling approach using nonlinear mixed-effects modeling (NONMEM). This statistical technique is well-suited for analyzing sparse and variable data, common in PK studies of complex biological agents like CAR T-cells.

  1. Base Model Development: They adapted a previously established PopPK model for another CAR T-cell therapy (tisagenlecleucel). This model describes CAR T-cell kinetics as an initial expansion phase followed by a biexponential contraction (a rapid decline and a slower, persistent decline).
  2. Covariate Analysis: They systematically investigated various patient and disease factors (covariates) that might influence the PK parameters. These included demographics, prior treatments (auto-HSCT, other CAR T-cell therapies), extramedullary lesions, and CRS grade.
  3. Model Modification: Based on the covariate analysis, they refined the model. Specifically, they incorporated "extramedullary spreading" as a covariate affecting the maximum concentration (Cmax).
  4. Clonal Diversity Analysis: To understand the CAR T-cell population dynamics, they analyzed CAR integration sites in patients with sustained high CAR T-cell levels. This helped assess whether a single dominant clone was responsible for persistence.
  5. Effector/Memory Fraction Analysis: They also characterized the CAR T-cell populations into "effector" (rapidly declining) and "memory" (persistently high) fractions to see how these contributed to overall kinetics.

Datasets

The study utilized data from a phase I clinical trial of CT103A involving 18 patients with relapsed/refractory multiple myeloma. The dataset comprised 469 measurements of peripheral CT103A transgene copy numbers over time, collected using droplet digital polymerase chain reaction (ddPCR).

Key Insights and Ideas

  • Memory Matters More Than Clones: The most significant finding is that the long-term persistence of CT103A is driven by a substantial memory CAR T-cell fraction, not by the emergence of a single dominant clone. This suggests that the therapy engenders a resilient population of CAR T-cells capable of sustained activity.
  • Extramedullary Disease is a Hurdle: The presence of extramedullary lesions was found to significantly impair the peak concentration (Cmax) of CT103A. This implies that while CT103A can still be effective, its ability to reach high levels in the bloodstream might be compromised in patients with widespread disease outside the bone marrow.
  • Standard CRS Treatments Don't Hinder Expansion: Importantly, the study found that common treatments for cytokine release syndrome (CRS), such as tocilizumab and corticosteroids, did not negatively impact the expansion rate or long-term efficacy of CT103A. This is a crucial piece of information for managing potential side effects without compromising treatment effectiveness.
  • Dose-Response Nuances: While higher doses of CT103A didn't show an increased probability of response at early time points (day 14), they were associated with a higher incidence of severe CRS. This suggests a potential trade-off, leading to a recommendation for a lower dose (1 × 10⁶ cells/kg) for a better balance of efficacy and safety.

Key Results

  • A PopPK model was successfully developed and validated for CT103A, capturing its complex kinetics.
  • Extramedullary spreading was identified as a significant covariate, negatively impacting Cmax (p = 0.0258).
  • Patients with prior auto-HSCT or extramedullary spreading had significantly lower AUC0-28 (area under the curve over 28 days), indicating reduced overall exposure.
  • Tocilizumab and corticosteroids showed no statistically significant impact on the expansion rate (p close to 1).
  • Analysis of CAR integration sites in patients with sustained high CT103A levels revealed no dominant clone, suggesting a polyclonal response.
  • Patients with lower contraction rate constants (α and β) and higher Cmax, along with a higher memory CAR T-cell fraction, achieved better clinical responses.
  • No significant difference in response probability was observed at day 14 across different doses, but 1 × 10⁶ CAR T-cells/kg was recommended due to safety considerations (lower severe CRS incidence).

Limitations and Future Work

  • Small Patient Cohort: The study was based on a relatively small cohort of 18 patients, particularly the subgroup of patients with progressive disease (PD) (n=4). This limits the statistical power for certain analyses and the generalizability of findings.
  • Phase I Study Data: The data comes from a Phase I study, which primarily focuses on safety and initial efficacy. Larger Phase II/III studies would provide more robust data for PK/PD modeling.
  • Model Specificity: The developed PopPK model and dose optimization recommendations are specific to CT103A and BCMA-targeting CAR T-cell therapy. They may not be directly applicable to other CAR T-cell products or targets.

Future work could involve validating these findings in larger, prospective studies. Further exploration into the specific mechanisms by which the memory CAR T-cell fraction contributes to long-term persistence and how extramedullary disease influences CAR T-cell trafficking and function would be valuable. Additionally, refining dose optimization strategies based on individual patient characteristics and disease burden could enhance treatment outcomes.

Summary updated

Abstract

Different from canonical drugs, CAR T-cells are "living drugs", which derived from patient's own blood. Studies of the pharmacokinetics of CAR T-cells could improve our understanding of their efficacy, safety, optimal dosage, and other characterizes. We previously reported a phase I study of a novel fully human BCMA-targeting CAR (CT103A) in 18 patients with relapsed/refractory multiple myeloma. CT103A exhibited extraordinary persistence with low anti-drug antibody positivity. To figure out the pharmacokinetic characterizes and investigate the potential reason of CT103A's long-term persistence, we established a population pharmacokinetic (PopPK) model of CT103A based on 18 patients cohort by applying nonlinear mixed-effects modeling and analyzed the CAR T-cell clonal evolution. The results suggested that extramedullary spreading was found to impair C<sub>max</sub> and was therefore added as a covariate to the modified model. The model revealed tocilizumab and corticosteroids showed no impact on the CT103A expansion rate. No dominant clone existed in patients with persistently high peripheral CT103A by CAR integration sites analysis. Finally, patients with lower contraction rate constants and higher C<sub>max</sub> as well as memory CT103A fraction could achieve better clinical responses. Taken together, this study developed a PopPK model of a fully human anti-BCMA CAR T-cell therapy, and summarized its model characteristics. We suggested that the long-term persistence of CT103A was attributed to the memory CAR T-cell fraction but not the clonal evolution. This study will improve people's understanding of pharmacokinetics and PopPK of CAR T-cell immunotherapy.
BibTeX
@inproceedings{mu2022model,
  author = {Wei Mu and Xiaolu Long and Haodong Cai and Caixia Chen and Guang Hu and Yaoyao Lou and Shugang Xing and Di Wang and Jue Wang and Min Xiao and Kun Wang and Zhongyi Sun and Chunrui Li and Jianfeng Zhou and Liting Chen},
  title = {{A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.803693},
}
Figure